LOCALLY MANUFACTURED AUTOLOGOUS CD19 CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELLS FOR PHASE II PROSPECTIVE CLINICAL TRIAL FOR RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA IN MALAYSIA

被引：0
|
作者：
Lim, T. S. [1 ]
Nyunt, W. [1 ]
Then, K. [2 ]
Cheong, S. [2 ]
Then, K. [2 ]
Ooi, G. [2 ]
Govindasamy, V. [2 ]
Idris, M. Mohd [3 ]
Azura, S. [3 ]
Abdullah, N. [3 ]
Zakaria, M. Muhd [3 ,4 ]
Chang, A. H. [6 ]
Ithnin, A. [7 ]
Wahid, S. S. Abdul [3 ,5 ]
机构：
[1] Plutonet Sdn Bhd, Cyberjaya, Malaysia
[2] Cryocord Sdn Bhd, Cyberjaya, Malaysia
[3] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Pusat Terapi Sel PTS, Kuala Lumpur, Malaysia
[4] Prince Court Med Ctr, Kuala Lumpur, Malaysia
[5] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[6] Shanghai YaKe Biotechnol Ltd, Shanghai, Peoples R China
[7] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Dept Pathol, Kuala Lumpur, Malaysia
来源：
CYTOTHERAPY | 2023年 / 25卷 / 06期
关键词：
CAR-T therapy; CAR-T manufacturing;
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
1028
引用
收藏
页码：S225 / S226
页数：2
相关论文
共 50 条
  • [1] CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
    Maus, Marcela V.
    LANCET, 2021, 398 (10299): : 466 - 467
  • [2] Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia
    Wang, Shiyuan
    Wang, Xue
    Ye, Chunying
    Cheng, Hai
    Shi, Ming
    Chen, Wei
    Qi, Kunming
    Wang, Gang
    Wu, Qingyun
    Zeng, Lingyu
    Li, Zhenyu
    Jing, Guangjun
    Zheng, Junnian
    Xu, Kailin
    Cao, Jiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E162 - E165
  • [3] Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
    Shi, Ming
    Li, Li
    Wang, Shiyuan
    Cheng, Hai
    Chen, Wei
    Sang, Wei
    Qi, Kunming
    Li, Zhenyu
    Wang, Gang
    Li, Huizhong
    Lan, Jianping
    Huang, Jinqi
    Fei, Xiaoming
    Yu, Min
    Li, Fei
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Jing, Guangjun
    Zheng, Junnian
    Gale, Robert Peter
    Xu, Kailin
    Cao, Jiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 711 - 718
  • [4] CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS TARGETING THE CD19 ANTIGEN FOR THE TREATMENT OF RELAPSED B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
    Curran, Kevin
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S6 - S6
  • [5] Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia
    Dourthe, Marie Emilie
    Yakouben, Karima
    David, Audrey
    Thouvenin, Sandrine
    Chaillou, Delphine
    Caillat-Zucman, Sophie
    Cuffel, Alexis
    Tardy, Clea
    Lainey, Elodie
    Caye-Eude, Aurelie
    Arfeuille, Chloe
    Delaugerre, Constance
    Chaix-Baudier, Marie-Laure
    Naudin, Jerome
    Auvin, Stephane
    Bergaoui, Karim
    Merlat-Guitard, Anne-Isabelle
    De Jorna, Romain
    Mebarki, Miryam
    Dalle, Jean-Hugues
    Baruchel, Andre
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (01) : 373 - 377
  • [6] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Gu, Runxia
    Liu, Fang
    Zou, Dehui
    Xu, Yingxi
    Lu, Yang
    Liu, Bingcheng
    Liu, Wei
    Chen, Xiaojuan
    Liu, Kaiqi
    Guo, Ye
    Gong, Xiaoyuan
    Lv, Rui
    Chen, Xia
    Zhou, Chunlin
    Zhong, Mengjun
    Wang, Huijun
    Wei, Hui
    Mi, Yingchang
    Qiu, Lugui
    Lv, Lulu
    Wang, Min
    Wang, Ying
    Zhu, Xiaofan
    Wang, Jianxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [7] MANAGING RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS ON A PHASE I TRIAL RECEIVING AUTOLOGOUS CAR (CHIMERIC ANTIGEN RECEPTOR) T-CELLS GENETICALLY MODIFIED TO TARGET B CELL SPECIFIC ANTIGEN CD19
    Quintanilla, Hilda S.
    Miale-Mayer, Donna
    Llerandi, Diane
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E102 - E103
  • [8] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Runxia Gu
    Fang Liu
    Dehui Zou
    Yingxi Xu
    Yang Lu
    Bingcheng Liu
    Wei Liu
    Xiaojuan Chen
    Kaiqi Liu
    Ye Guo
    Xiaoyuan Gong
    Rui Lv
    Xia Chen
    Chunlin Zhou
    Mengjun Zhong
    Huijun Wang
    Hui Wei
    Yingchang Mi
    Lugui Qiu
    Lulu Lv
    Min Wang
    Ying Wang
    Xiaofan Zhu
    Jianxiang Wang
    Journal of Hematology & Oncology, 13
  • [9] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Yang, Tingting
    Dong, Yetian
    Zhang, Mingming
    Feng, Jingjing
    Fu, Shan
    Xiao, Pingnan
    Hong, Ruimin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Wei, Guoqing
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    BLOOD, 2024, 144 : 2819 - 2819
  • [10] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
    Lihong An
    Yuehui Lin
    Biping Deng
    Zhichao Yin
    Defeng Zhao
    Zhuojun Ling
    Tong Wu
    Yongqiang Zhao
    Alex H. Chang
    Chunrong Tong
    Shuangyou Liu
    BMC Cancer, 22
12345